



PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Oncology

Manuscript NO: 47457

Title: Precision medicine for gastrointestinal cancer: Recent progress and future perspective

Reviewer’s code: 00504708

Position: Editorial Board

Academic degree: MD

Professional title: Associate Professor,N/A

Reviewer’s country: United States

Science editor: Ying Dou

Reviewer accepted review: 2019-05-30 11:59

Reviewer performed review: 2019-05-30 12:28

Review time: 1 Hour

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input checked="" type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer’s expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input checked="" type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input checked="" type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

I commend the authors for realizing significant trends toward more precise diagnosis



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-223-8242
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

and treatment of gastrointestinal malignancy. This is certainly the likely path for practitioners in this field. However the authors must make it clear we are in the very very early phases of this transition towards precision and personalized medicine. It is likely that few of the mentioned targeted tools or treatment markers will be utilized a decade from now. Most of the manuscript is very well written. I do take exception to several points however. The sentence "Ineffective drugs can cause progression of cancer without producing any benefit" is patently wrong. Also, colorectal cancer-at least in my experience- has been significantly impacted by the use of colonoscopy as a screening modality. In addition, even patients with widespread CRC may entertain long-term survival and even occasional cure. Gastrointestinal lymphoma such as MALT may also be associated with good response and prolonged survival. In terms of content, perhaps the authors should cover organoids where a patient's tumor is analyzed for both personal treatment and research in the field. In sum, this is an excellent choice of topic and the authors did a reasonable job in covering this broad and complex field. I would just temper some of the statements made.

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:

- The same title
- Duplicate publication
- Plagiarism
- No

BPG Search:

- The same title
- Duplicate publication



Baishideng Publishing Group

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA

Telephone: +1-925-223-8242

E-mail: bpgoffice@wjgnet.com

https://www.wjgnet.com

[] Plagiarism

[Y] No



PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Oncology

Manuscript NO: 47457

Title: Precision medicine for gastrointestinal cancer: Recent progress and future perspective

Reviewer’s code: 00051398

Position: Editorial Board

Academic degree: PhD

Professional title: Professor

Reviewer’s country: Lebanon

Science editor: Ying Dou

Reviewer accepted review: 2019-05-30 07:55

Reviewer performed review: 2019-06-10 08:55

Review time: 11 Days

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input checked="" type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer’s expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input checked="" type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input checked="" type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

The review has provided an extensive search of the literature on genomic aberrations



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-223-8242
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

identified in patients with GI cancer. reported Biomarkers from biological fluids including: blood, urine, seum, plasma, pleural effusion and CSF were summarized in 3 tables. This review may be of clinical value in future if more data are collected, as it will possibly identify biomarkers of prognostic, cost effective and therapeutic predictive value in Patients with GI cancer. The write up as far as language is very good but going through it was not easy possibly because of the many biomarkers and differences between CTCs, ctDNA, MiRNA...etc. the tables as presented were also complicated specially table-1. i am not sure if clinical implication may be presented along with targets in a separate table. alternatively separate table for CTSC, miRNA. Table 2 under publication PMID it is better to be consistent including only PMID number as in table 1 and 3. why listing there the authors? the tables are too crowded. some of the indicators for instance TP53 is common, one can add in the table foot note it is common to all except... minor typos to be corrected in text and TABLES.

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:

- The same title
- Duplicate publication
- Plagiarism
- No

BPG Search:

- The same title
- Duplicate publication
- Plagiarism
- No